An Analysis of the Initial Adoption of Fas 141 and 142 in the Pharmaceutical Industry

By Duchac, Jonathan; Douthett, Ed | Academy of Accounting and Financial Studies Journal, September 1, 2006 | Go to article overview
Save to active project

An Analysis of the Initial Adoption of Fas 141 and 142 in the Pharmaceutical Industry


Duchac, Jonathan, Douthett, Ed, Academy of Accounting and Financial Studies Journal


ABSTRACT

In 2001 the Financial Accounting Standards Board issued FAS 141 Business Combinations, and FAS 142 Goodwill and Intangible Assets. These new accounting standards significantly changed the accounting for mergers and acquisitions, dramatically altering how business combinations are reflected in the surviving company's financial statements. These new rules are particularly relevant for companies in industries that rely heavily on intellectual capital to generate future cashflows, or those that are characterized by considerable mergers and acquisitions activity.

Documenting how these new standards are initially applied provides valuable insight into their impact on the structure and content of the resulting financial statements. This study addresses this issue by examining and documenting initial FAS 141 and 142 disclosures for firms in the pharmaceutical industry. We focus on the pharmaceutical industry because it is dominated by a few well defined business models, and is characterized by firms that rely heavily on intangible assets and have considerable mergers and acquisitions activity.

The results of our analysis identify several emerging trends within the pharmaceutical industry. First, strategic analysis indicates that a variety of business models currently exist in the pharmaceutical industry, and most pharmaceutical companies pursue more than one business model. Second, financial disclosure analysis reveals that although different business models led to some variation in disclosures, disclosure practice across firms in the pharmaceutical industry is fairly consistent. Finally, analysis of recent acquisitions provides evidence of consistent reporting and disclosure of purchase type business combinations under FAS 141 and 142. These results provide a benchmark/or industry practice that can be used to identify trends in financial reporting and disclosure related to these two accounting standards.

INTRODUCTION

In 2001 the Financial Accounting Standards Board issued FAS 141 Business Combinations, and FAS 142 Goodwill and Intangible Assets. These new accounting standards represented a significant shift in the accounting for mergers and acquisitions, and dramatically changed how business combinations are reflected in the surviving company's financial statements. The most notable aspects of these new accounting rules were the elimination of the pooling-of-interest method of accounting for business combinations, the elimination of the periodic amortization of goodwill in favor of an impairment testing model, and the requirement that identifiable intangible assets be recognized separately in a business combination. These changes were particularly relevant for companies in industries that rely heavily on intellectual capital to generate future cash flows, or those that are characterized by considerable mergers and acquisitions activity.

Documenting how these standards are initially applied provides valuable insight into how these changes affect the structure and content of the resulting financial statements. This study addresses this issue by examining and documenting initial FAS 141 and 142 disclosures for firms in the pharmaceutical industry. We focus on the pharmaceutical industry because it is represented by a few well defined business models, and is characterized by firms that rely heavily on intangible assets and have considerable mergers and acquisitions activity. The analysis reviews financial disclosures of a sample of publicly listed pharmaceutical companies, documenting how these companies implement the new accounting standards, and examining the consistency in which these standards are applied. The results provide a benchmark for industry practice in the application of FAS 141 and 142. This data can then be used to identify trends in financial reporting and disclosure related to FAS 141 and FAS 142.

The study examines three categories of pharmaceutical companies that are directly related to business combinations and intangible assets: (1) company strategy and lines of business, (2) goodwill and intangible asset disclosures, and (3) strategic acquisitions.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

An Analysis of the Initial Adoption of Fas 141 and 142 in the Pharmaceutical Industry
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?